Esther G.M. De Waal

Progression of a solitary plasmacytoma to multiple myeloma. A population‐based registry of the northern Netherlands

Esther G.M. De Waal, Marnix J. Leene, Nic J.G.M. Veeger et al. · British Journal of Haematology · 2016 · 78 citations · Full text

Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study

Claudia A.M. Stege, Kazem Nasserinejad, Ellen van der Spek et al. · Journal of Clinical Oncology · 2021 · 60 citations · Full text

Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients

Esther G.M. De Waal, Linda de Munck, Mels Hoogendoorn et al. · British Journal of Haematology · 2015 · 20 citations · Full text

Hematological Malignancy, Health Sciences, Maintenance Treatment +12

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study

Claudia A.M. Stege, Kazem Nasserinejad, Ellen van der Spek et al. · Blood · 2019 · 15 citations

Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial

K. Groen, Claudia A.M. Stege, Kazem Nasserinejad et al. · EClinicalMedicine · 2023 · 13 citations · Full text